首页> 外文期刊>World Journal of Gastroenterology >New tumor-associated antigen SC6 in pancreatic cancer.
【24h】

New tumor-associated antigen SC6 in pancreatic cancer.

机译:胰腺癌中新的肿瘤相关抗原SC6。

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: To examine the concentration of a new antigen SC6 (SC6-Ag) recognized by monoclonal antibody (MAb) in patients with pancreatic cancer and other malignant or benign diseases and to understand whether SC6-Ag has any clinical significance in distinguishing pancreatic cancer from other gastrointestinal diseases. METHODS: Six hundred and ninety-five serum specimens obtained from 115 patients with pancreatic cancer, 154 patients with digestive cancer and 95 patients with non-digestive cancer were used and classified in this study. Serum specimens obtained from 140 patients with benign digestive disease and 89 patients with non-benign digestive disease served as controls. Ascites was tapped from 16 pancreatic cancer patients, 19 hepatic cancer patients, 16 colonic cancer patients, 10 gastric cancer and 6 severe necrotic pancreatitis patients. The samples were quantitated by solid-phase radioimmunoassay. The cut-off values (CV) of 41, 80, and 118 U/mL were used. RESULTS: The average intra- and interassay CV detected by immunoradiometric assay of SC6-Ag was 5.4% and 8.7%, respectively. The sensitivity and specificity were 73.0% and 90.9% respectively. The levels in most malignant and benign cases were within the normal upper limit. Among the 16 pancreatic cancer cases, the concentration of SC6-Ag in ascites was over the normal range in 93.8% patients. There was no significant difference in the concentration of SC6-Ag. Decreased expression of SC6-Ag in sera was significantly related to tumor differentiation. The concentration of SC6-Ag was higher in patients before surgery than after surgery. The specificity of SC6-Ag and CA19-9 was significantly higher than that of ultrasound and computer tomography (CT) in pancreatic cancer patients. Higher positive predictive values were indicated in 92.3% SC6-Ag and 88.5% CA19-9, but lower in 73.8% ultrasound and 76.2% CT. CONCLUSION: The combined test of SC6-Ag and CA19-9 may improve the diagnostic rate of primary cancer. The detection of SC6-Ag is valuable in the diagnosis of pancreatic cancer before and after surgery.
机译:目的:检查胰腺癌和其他恶性或良性疾病患者中单克隆抗体(MAb)识别的新抗原SC6(SC6-Ag)的浓度,并了解SC6-Ag在区分胰腺癌和胰腺癌方面是否具有任何临床意义。其他胃肠道疾病。方法:对115例胰腺癌,154例消化道癌和95例非消化道癌患者的695份血清标本进行了分类。取140例良性消化系统疾病患者和89例非良性消化系统疾病患者的血清标本作为对照。从16例胰腺癌患者,19例肝癌患者,16例结肠癌患者,10例胃癌和6例严重坏死性胰腺炎患者中抽取腹水。通过固相放射免疫测定法定量样品。截断值(CV)为41、80和118 U / mL。结果:通过免疫放射分析法测得的SC6-Ag的平均批内和批间CV分别为5.4%和8.7%。敏感性和特异性分别为73.0%和90.9%。大多数恶性和良性病例的水平均在正常上限范围内。在16例胰腺癌患者中,有93.8%的患者腹水中SC6-Ag的浓度高于正常范围。 SC6-Ag的浓度没有显着差异。血清中SC6-Ag的表达降低与肿瘤分化显着相关。手术前患者中SC6-Ag的浓度高于手术后。在胰腺癌患者中,SC6-Ag和CA19-9的特异性显着高于超声和计算机断层扫描(CT)。 92.3%的SC6-Ag和88.5%的CA19-9显示较高的阳性预测值,而73.8%的超声和76.2%的CT显示较低。结论:SC6-Ag和CA19-9联合检测可提高原发癌的诊断率。 SC6-Ag的检测对手术前后胰腺癌的诊断具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号